… In this study (ElderTac: erlotinib in routine clinical practice in elderly patients with NSCLC),
we … Nevertheless, our observational study generated invaluable results for real-life treatment …

… ] of observation for all patients receiving erlotinib during … study are comparable to those
from clinical trials of erlotinib, despite our study population having a high proportion of patients …

… We acknowledge that there are several limitations of this study, including the fact that this
was a single-arm observational study with no control group, and the lack of a strict observation …

… Consistent with this observation, a substantial proportion of patients in this study (39%)
experienced disease stabilization. The lack of correlation between HER1/EGFR expression and …

… of the OS benefit in the current study compared with the SATURN trial. However, … erlotinib
was still associated with a slight OS benefit in our study, despite the fact that nearly all patients …

… , intracranial progression developed sooner (median: 8.9 months, 95% CI: 9.10 to 14.93)
in our patients treated with erlotinib, but the difference was not significant. The gefitinib-treated …

… ) study was the first prospective phase III trial of erlotinib versus chemotherapy in non-Asian
patients … in the first-line treatment decisions for patients in this study, because of the known …

… did not experience progression, and 919 were alive at the last observation. Data for these
… erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. …

… Observation and evaluation of AEs was conducted as appropriate throughout the … study
was conducted on the basis of results from a phase I study of erlotinib in Japanese patients with …

… the first-generation reversible EGFR TKIs erlotinib and gefitinib in head-to-head … erlotinib,
and afatinib being the emergence of the “gatekeeper” T790M mutation (in ~ 50–70% of patients…